RECRUITING

Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

Description

This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression.

Conditions

REM Behavior DisorderParkinson Disease
Talk to us

Related Conditions:

REM Behavior DisorderParkinson Disease

Study Overview

On this page

Study Details

Study overview

This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression.

Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

Condition
REM Behavior Disorder
Intervention / Treatment

-

Contacts and Locations

Scottsdale

CND Life Sciences, Scottsdale, Arizona, United States, 85258

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male and female 50 to 100 years of age
  • 2. Clinical confirmed diagnosis of Parkinson\'s disease or REM Sleep Behavior
  • 1. Clinical evidence of severe vascular disease (history of ulceration, poor wound healing or vascular claudication)
  • 2. History of allergic reaction to Lidocaine for local anesthesia needed for skin biopsies
  • 3. Use of blood thinners (Plavix or Aspirin used separately is allowed)
  • 4. Significantly impaired wound healing or history of scarring or keloid formation

Ages Eligible for Study

50 Years to 100 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

CND Life Sciences,

Todd Chief Medical Officer, PRINCIPAL_INVESTIGATOR, CND Life Sciences

Study Record Dates

2026-04